The aim of the current research was to evaluate the effectiveness of extracorporeal shock wave treatment and local corticosteroid injection in management of tennis elbow in athletes both clinically and ultrasonographically. In our study, the highly significant productivity of ESWT on pain and operational incapacity parameters symbolized in VAS, PRTEE, and Quick DASH test showed a high significant improvement among ESWT group before and after 2, 4, 8, and 12 week. This is concurred with Maffulli et al. [17], who performed a research on 59 patients with LE obtaining 3 sessions of ESWT. He stated a significant progress concerning the VAS score and PRTEE score after 3, 6, 12, and 24 months of follow-up. Similarly, Ismael et al. [18] and Aydin and Atic [19] stated that there were a statistically considerable reduction of VAS and PRTEE scores and a substantial expansion of functional measure represented in hand grip intensity at 4 weeks of follow-up and 12 weeks of follow-up in the ESWT group.
In contrast, Buchbinder et al. [20] performed a systematic review and described that there was an evidence that extracorporeal shock wave therapy offered no or little impact in pain and purpose in LE patients.
In some studies, the efficacy of shock wave therapy in the treatment of lateral epicondylitis has been investigated, and success rates ranging between 68 and 91% have been reported [21]. However, some studies have showed that shock wave therapy has either no therapeutic effect or been less effective than the placebo [20, 21].
In a pool study achieved by Reza Nourbakhsh et al. [22] and Mehra et al. [23] regarding ESWT, the authors stated 50% pain relief within 12 weeks of follow-up period with ESWT. Spacca et al. [24] reported a significant pain relief with shock wave therapy within 12 weeks of the follow-up period when compared with the placebo.
Collins and Jafarnia [25] also found a significant decrease in pain aggravation with activity using ESWT during 8 weeks of the follow-up period.
The cause for the contradictory findings of ESWT on LE might be the variations in the pulses number, duration, frequency, treatment interval, and diverse devices applied, relying on the variable protocols applied in treatment. This may be when the literature is amended, it is seen that ESWT does not have a standard protocol used for medication of LE.
When a shock wave targets a tissue, it produces two physical effects: The stress-associated phenomenon persuaded by the ultra-short upsurge time about 5 ns and the cavitation bubbles formed at the edge between the solid and the neighboring liquid. These two actions work synergically to produce the short-wave effect. ESWT promotes soft tissue healing mainly by suppressing afferent pain-receptor function in the first hours After that, in the next few days, by downregulating the production of inflammatory cytokines [26], and by increasing the angiogenesis and, at about the 28-30th day, by refining cellular proliferation and the creation of the extra-cellular matrix [27].
In our study, the highly significant efficacy of CS injection on pain and functional incapacity parameters such as VAS, PRTEE, and Quick DASH test showed a high significant improvement among CS injection group after 2, 4, 8, and 12 weeks of treatment. This is in parallel to the study of Smidt et al. [28] that contained thirteen studies, to assess the efficiency of CS injection compared to placebo administration, local anesthetic insertion, or another traditional therapy in LE. For short-term effects (≤ 6 weeks), there were significant differences that were observed on pain relief, global improvement, and hand grip intensity for CS insertion equated to other therapy alternatives. Similar outcomes also have been informed by others in the literature [29, 30].
Ismael et al. [18] also reported a significant reduction of VAS and PRTEE totals at 4 and 12 weeks of follow-up.
Conversely, Lindenhovius et al. [31] compared CS injection to placebo insertion and found no meaningful variations in the pain and functional incapacity scores, in both short-term and long-term follow-up.
Newcomer et al. [32] also noticed no significant variations in the VAS and functional results, even in the short-term, in the steroid infusion group related to the placebo insertion group.
In the present study, VAS test showed a highly significant improvement among ESWT group after 2, 4, 8, and 12 weeks with p < 0.001. These results are agreed with Pettrone and McCall [33] who found a high significant alleviation of pain intensity by VAS among LE patients who received ESWT.
Although the diagnosis of LE is mostly clinical, due to its countless benefits, US has been utilized as a useful imaging technique for the finding and follow-up of LE [34]. Ultrasound results in lateral epicondylitis have been well recognized with both structural variations [5] (tendon thickening, hypoechogenicity, intrasubstance tears, intratendon calcification, and bone spurs) and blood flow alterations or neovascularity [35]. Hypo echogenicity of common extensor origin tendon (CEO) is a strong evidence of chronic rather than acute LE. It reflects a chronically overused tendon [36]. In the current study, there was no statistically substantial alteration among the considered groups according to US changes (focal areas of hypo-echogenicity) through follow-up periods (2, 4, 8, and 12 weeks) and a statistically significant variance in favor of ESWT group regarding tendon thickening after 2 and 4 weeks of treatment. Other US parameters such as disturbed fibrillar pattern, intratendon calcification, and bone spurs, and power Doppler signals did not reveal considerable differences between the 2 groups although the ESWT group showed better US outcome. Up to date, no previous studies have used the musculoskeletal ultrasound in the comparison of outcome of both corticosteroid injection and ESWT.
Clarke et al. [37] evaluated sonographic prophets for tendon healing in patients with LE tendinopathy and noticed no parallel with clinical results and thickness of the tendon. Zeisiq et al. [34] tracked up 25 patients with LE after intertendinous injection treatment but could not reveal a correlation with structural variations in US and clinical findings.
In this study, there was a significant improvement in ESWT patients 2, 4, 8, and 12 weeks after treatment than local CS injection group which in line with the results of Lee et al. [4] who matched the usefulness of ESWT and corticosteroid insertion on patients with recently diagnosed LE and medial epicondylitis. They determined that ESWT was effectively considered as injections after therapy and during the 8-week follow-up.
Ozturan et al. [38] alienated 60 patients with a complaint > 6 months into 3 treatment groups and compared the effectiveness of corticosteroid injection, autologous blood, injection, and ESWT. In their study, while assessing patients with the Thompson test, upper-extremity function scores, and grip strength during a 52-week follow-up were assessed. He reported that the corticosteroid group was improved to the other groups at 4 weeks in terms of VAS and grip strength, but this superiority did not continue in the subsequent follow-ups. It was stated at 52 weeks of follow-up period that the corticosteroid injection had a success rate of 50%, autologous blood injection had a success rate of 83%, and ESWT had a success rate of 89%. Eraslan et al. [39] drew similar conclusions. Thus, ESWT seems to validate greater long-term efficiency than corticosteroid injection.
However, this study has some limitation, including the relatively small sample size, few numbers of ESWT sessions (3 sessions only), and relatively short assessment period which was only 12 weeks.